Tian Ji - Concord Medical Independent Director
| CCM Stock | USD 0.57 0.01 1.71% |
Director
Mr. Ji Tian is Independent Director of the company. Mr. Ji Tian is currently the deputy general manager of Gopher Asset Management. Before joining Gopher Asset Mr. Ji was the head of managed accounts department of AXA SPDB Investment Managers. From 2009 to 2011 Mr. Ji worked in at Wanjia Asset Management covering equity research and macro economy research. From 2006 to 2009 Mr. Ji worked at the equity derivatives department of ABN AMRO Bank. Mr. Ji received a master degree of business management in Fudan Management School and a bachelor degree of mathematics in Fudan University since 2013.
| Tenure | 11 years |
| Professional Marks | CFA |
| Address | Tower A, Global Trade Center, Beijing, China, 100013 |
| Phone | 86 10 5903 6688 |
| Web | https://www.concordmedical.com |
Concord Medical Management Efficiency
The company has Return on Asset of (0.048) % which means that on every $100 spent on assets, it lost $0.048. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2823) %, meaning that it generated no profit with money invested by stockholders. Concord Medical's management efficiency ratios could be used to measure how well Concord Medical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of April 2024, Return On Equity is likely to grow to 0.18, while Return On Tangible Assets are likely to drop (0.06). At this time, Concord Medical's Other Current Assets are very stable compared to the past year. As of the 25th of April 2024, Intangible Assets is likely to grow to about 400.1 M, while Other Assets are likely to drop about 26.2 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| John Ruffle | American Shared Hospital | 78 | |
| Emil Hassan | National HealthCare | 72 | |
| Sandra Lawrence | American Shared Hospital | 61 | |
| Katherine Davisson | Select Medical Holdings | 53 | |
| Julie Korinke | Oncology Institute | N/A | |
| Andrew Adams | National HealthCare | 72 | |
| Donald Correll | Encompass Health Corp | 70 | |
| Mert Ozyurek | American Shared Hospital | 39 | |
| Paul Abernathy | National HealthCare | 82 | |
| Daniel Thomas | Select Medical Holdings | 62 | |
| Leslye Katz | Encompass Health Corp | 66 | |
| Malene Davis | The Ensign Group | 55 | |
| William Frist | Select Medical Holdings | 69 | |
| Russell Carson | Select Medical Holdings | 77 | |
| William Fields | The Joint Corp | 65 | |
| Ernest Burgess | National HealthCare | 79 | |
| Ann Blouin | The Ensign Group | 65 | |
| Jim Amos | The Joint Corp | N/A | |
| John Maupin | Encompass Health Corp | 73 | |
| Richard Kerley | The Joint Corp | 67 | |
| Daren Shaw | The Ensign Group | 61 | |
Management Performance
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.048 |
Concord Medical Services Leadership Team
Elected by the shareholders, the Concord Medical's board of directors comprises two types of representatives: Concord Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Concord. The board's role is to monitor Concord Medical's management team and ensure that shareholders' interests are well served. Concord Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Concord Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Xun Liu, Financial Controller | ||
| Shangyan Chuang, Director | ||
| Matthew Callister, Chief Medical Officer | ||
| Zhang Liping, Independent Director | ||
| Shang Chuang, Director | ||
| Jianyu Yang, Chairman, CEO, Chairman of Compensation Committee and Member of Investment Committee | ||
| Boxun Zhang, Independent Director | ||
| Jing Zhang, Chief Administrative Officer | ||
| Weibo Yin, Independent Director and Member of Audit Committee | ||
| William Zima, IR Contact Officer | ||
| Jigang Sun, Chief Investment Officer and Chairman of Investment Committee | ||
| Yue Yu, Director | ||
| Sui Yan, Director | ||
| Zheng Cheng, President, Director and Member of Investment Committee | ||
| Qing Pan, Director | ||
| Elaine Zong, Independent Director | ||
| Yongjun Li, Independent Director | ||
| Fu Xiao, Chief Operating Officer | ||
| Yaw Yap, CFO and Member of Investment Committee | ||
| Ting Lee, Independent Non-Executive Director | ||
| Liping Zhang, Independent Director | ||
| Tian Ji, Independent Director | ||
| Zhe Yin, Independent Director |
Concord Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Concord Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.048 | ||||
| Profit Margin | (0.55) % | ||||
| Operating Margin | (0.98) % | ||||
| Current Valuation | 7.18 B | ||||
| Shares Outstanding | 43.42 M | ||||
| Shares Owned By Insiders | 17.99 % | ||||
| Shares Owned By Institutions | 0.10 % | ||||
| Number Of Shares Shorted | 14.54 K | ||||
| Price To Earning | (3.90) X |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Concord Medical Services. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Concord Medical Services information on this page should be used as a complementary analysis to other Concord Medical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Concord Stock analysis
When running Concord Medical's price analysis, check to measure Concord Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Concord Medical is operating at the current time. Most of Concord Medical's value examination focuses on studying past and present price action to predict the probability of Concord Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Concord Medical's price. Additionally, you may evaluate how the addition of Concord Medical to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Concord Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Concord Medical. If investors know Concord will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Concord Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.94) | Revenue Per Share 12.302 | Quarterly Revenue Growth (0.23) | Return On Assets (0.05) | Return On Equity (0.28) |
The market value of Concord Medical Services is measured differently than its book value, which is the value of Concord that is recorded on the company's balance sheet. Investors also form their own opinion of Concord Medical's value that differs from its market value or its book value, called intrinsic value, which is Concord Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Concord Medical's market value can be influenced by many factors that don't directly affect Concord Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Concord Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Concord Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Concord Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.